Amgen Reports Third Quarter 2026 Financial Results

Amgen posts 8% revenue growth and double-digit EPS gains, driven by broad product strength.

What the company is saying

Amgen frames the quarter as a demonstration of its long-term growth strategy delivering tangible results, with CEO Robert A. Bradway emphasizing the strength of both the commercial portfolio and late-stage pipeline. The company highlights an 8% increase in total revenues to $10.4 billion and 8% product sales growth, attributing these gains primarily to volume increases. Seventeen products are said to have achieved double-digit sales growth, and seventeen are annualizing above $1 billion in sales, though the specific products are not listed. The narrative stresses robust profitability, with GAAP EPS up 19% to $7.08 and non-GAAP EPS up 14% to $6.45, both driven by higher revenues. Management explains the 5% decline in GAAP operating expenses as resulting from lower amortization and manufacturing costs, while increased R&D spending is acknowledged. The company also points to a 6% dividend increase and ongoing investment in its pipeline, notably the MariTide Phase 3 program.

What the data suggests

The disclosed numbers show Amgen's financial trajectory is strongly positive for Q3 2026. Total revenues rose 8% to $10.4 billion, with product sales reaching $9,883 million. GAAP EPS increased 19% to $7.08, and non-GAAP EPS rose 14% to $6.45. GAAP operating income jumped from $2.5 billion to $3.7 billion, with operating margin expanding by 9.9 percentage points to 37.5%. Free cash flow was $3.7 billion, down from $4.2 billion, explained by working capital timing. Product-level data reveals standout growth in Repatha (up 37% to $1,085 million), EVENITY (up 39% to $751 million), and UPLIZNA (up 191% to $451 million), while Prolia and XGEVA saw sharp declines due to biosimilar competition. R&D expenses increased 11%, reflecting pipeline investment. The company ended the quarter with $13.2 billion in cash and $54.0 billion in debt. Full-year guidance targets $38.9–$39.7 billion in revenue and $18.34–$19.28 GAAP EPS. The evidence supports management's claims of broad-based growth, though some qualitative assertions (such as the exact products with double-digit growth) are not directly substantiated.

Analysis

The announcement's tone is positive but proportionate to the substantial realised financial and operational progress disclosed. The majority of key claims are supported by concrete, audited figures: revenue, EPS, operating income, margins, and free cash flow are all reported with year-over-year growth. Forward-looking statements (full-year guidance, pipeline updates) are clearly separated from realised results and do not dominate the narrative. Capital expenditures and share repurchase plans are disclosed as guidance, but the benefits of the reported quarter are already realised and quantified. There is no evidence of narrative inflation or overstatement; the language is consistent with the scale of the results. The only minor inflation is in qualitative statements about 'strategy for long-term growth' and product annualisation, but these do not materially distort the investment signal.

Risk flags

• ●Biosimilar competition is materially eroding sales of key products like Prolia (down 45% to $632 million) and XGEVA (down 47% to $288 million), indicating ongoing vulnerability in mature franchises.
• ●Free cash flow declined from $4.2 billion to $3.7 billion year-over-year, driven by working capital timing, which could signal volatility in future quarters if rebate and collection cycles shift.
• ●Debt remains high at $54.0 billion, which, despite strong cash balances, could constrain flexibility if operating performance weakens or interest rates rise.
• ●R&D and capital expenditures are increasing (R&D up 11%, capex guidance at $2.6 billion for 2026), requiring continued commercial execution to justify the investment and avoid margin compression.
• ●Forward-looking guidance assumes continued volume-driven growth and successful pipeline execution; setbacks in late-stage trials or regulatory processes could undermine the growth narrative.

Bottom line

Amgen's Q3 2026 results confirm broad-based revenue and earnings growth, with 8% topline expansion and double-digit EPS gains supported by strong performance across multiple products. The company is successfully offsetting biosimilar-driven declines in legacy drugs with rapid growth in newer assets like Repatha, EVENITY, and UPLIZNA. Free cash flow remains robust but has declined year-over-year due to working capital timing, and the balance sheet carries significant debt. The pipeline, especially MariTide, is advancing but will not contribute near-term revenue. Investors should focus on the company's ability to sustain volume-driven growth, manage biosimilar erosion, and deliver on pipeline milestones. The most important takeaway is that Amgen's current commercial execution is strong, but ongoing product lifecycle management and pipeline delivery will be critical to maintaining this trajectory.

Announcement summary

(NASDAQ:AMGN) Amgen announced financial results for the third quarter of 2026, reporting total revenues of $10.4 billion, an 8% increase compared to the third quarter of 2025. Product sales also grew 8%, with seventeen products delivering at least double-digit sales growth and seventeen products annualizing at more than $1 billion based on third quarter sales. GAAP earnings per share (EPS) increased 19% from $5.93 to $7.08, driven by higher revenues. GAAP operating income rose from $2.5 billion to $3.7 billion, and GAAP operating margin increased 9.9 percentage points to 37.5%. Non-GAAP EPS increased 14% from $5.64 to $6.45, primarily due to higher revenues, partially offset by higher operating expenses. Non-GAAP operating income increased from $4.3 billion to $4.7 billion, and non-GAAP operating margin increased 0.2 percentage points to 47.3%. Free cash flow for the third quarter was $3.7 billion, compared to $4.2 billion in the prior year period. Repatha® sales increased 37% year-over-year to $1,085 million, EVENITY® sales increased 39% to $751 million, and Prolia® sales decreased 45% to $632 million. TEPEZZA® sales decreased 6% to $526 million, KRYSTEXXA® sales increased 31% to $419 million, UPLIZNA® sales increased 191% to $451 million, and TAVNEOS® sales decreased 2% to $105 million. TEZSPIRE® sales increased 43% to $538 million, Otezla® sales decreased 18% to $481 million, Enbrel® sales increased 5% to $611 million, AMJEVITA®/AMGEVITA™ sales increased 24% to $191 million, and PAVBLU® sales increased 41% to $300 million. BLINCYTO® sales increased 27% to $496 million, IMDELLTRA®/IMDYLLTRA™ sales increased 128% to $406 million, Vectibix® sales increased 18% to $335 million, KYPROLIS® sales decreased 8% to $330 million, LUMAKRAS®/LUMYKRAS™ sales increased 6% to $102 million, Nplate® sales increased 3% to $472 million, XGEVA® sales decreased 47% to $288 million, and MVASI® sales decreased 21% to $168 million. Established products, including Aranesp®, Neulasta®, and Parsabiv®, generated $606 million in sales, a 14% year-over-year increase. Total product sales for the quarter were $9,883 million, with $7,259 million from the U.S. and $2,624 million from the rest of the world. On a GAAP basis, total operating expenses decreased 5% year-over-year to $6,655 million, with cost of sales at $2,788 million, R&D expenses at $2,111 million, SG&A expenses at $1,680 million, and other expenses at $76 million. On a non-GAAP basis, total operating expenses increased 8% to $5,689 million. The company declared a third quarter dividend of $2.52 per share, paid on September 11, 2026, representing a 6% increase from the prior year. Cash and cash equivalents totaled $13.2 billion and debt outstanding was $54.0 billion as of September 30, 2026. For full year 2026, Amgen expects total revenues in the range of $38.9 billion to $39.7 billion, GAAP EPS of $18.34 to $19.28, non-GAAP EPS of $22.90 to $23.70, capital expenditures of approximately $2.6 billion, and share repurchases not to exceed $3.0 billion. The company provided updates on its pipeline, including multiple ongoing and completed Phase 3 studies for MariTide™ (maridebart cafraglutide/AMG 133) in chronic weight management, cardiovascular outcomes, heart failure, obstructive sleep apnea, and dosing schedule studies.

Disagree with this article?